Prognostic value of a 15-gene hypoxia classifier in oropharyngeal cancer treated with accelerated chemoradiotherapy.

Abstract

PURPOSE:

A 15-gene hypoxia classifier has been developed and validated as a predictive factor for patients with head and neck squamous cell carcinoma treated with radiotherapy and nimorazole. This paper aimed to investigate the role of this hypoxia classifier as a prognostic factor for patients with oropharyngeal cancer (OPC) treated with accelerated chemoradiotherapy.

METHODS:

P16 and 15-gene hypoxia classifier status, categorising tumours as more or less hypoxic, were determined for 136 OPC patients. Locoregional recurrence rate (LRR) and overall survival (OS) were estimated with cumulative incidence function and Kaplan-Meier method, respectively, stratified according to p16 and hypoxia status.

RESULTS:

P16-positive patients (34.6%) had significantly better LRR and OS than p16-negative patients. The 5‑year LRR of patients with more hypoxic OPC was similar to those with less hypoxic OPC in the overall patient population (27.3% versus 25.1%; p = 0.98; HR = 1.01 [CI95% 0.47;2.17]) and in the p16-negative OPC (36.4% versus 30.1%; p = 0.70; HR = 1.17 [CI95% 0.53;2.56]). No significant OS differences could be observed in neither p16-negative nor p16-positive subgroup with a 5-year OS for p16-negative more hypoxic OPC of 44.2% versus 49.0% in the less hypoxic OPC (p = 0.92; HR 0.97 [CI95% 0.51;1.84]).

CONCLUSION:

No significant outcome differences were observed between more or less hypoxic tumours, as determined by the 15-gene hypoxia classifier. These results suggest that the 15-gene hypoxia classifier may not have prognostic value in an OPC patient cohort treated with accelerated chemoradiotherapy.

• Authors: Sarah Deschuymer, Brita Singers Sørensen, Rüveyda Dok, Annouschka Laenen, Esther Hauben, Jens Overgaard, Sandra Nuyts
• Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (Strahlenther Onkol) Vol. 196 Issue 6 Pg. 552-560 (Jun 2020) ISSN: 1439-099X [Electronic] Germany
• PMID: 32080773 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Antineoplastic Agents, Alkylating
• Antineoplastic Agents, Immunological
• Cetuximab
• Cisplatin
• Oxygen

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents, Alkylating (therapeutic use)
• Antineoplastic Agents, Immunological (therapeutic use)
• Carcinoma, Squamous Cell (chemistry, genetics, mortality, therapy)
• Cell Hypoxia (genetics)
• Cetuximab (therapeutic use)
• Chemoradiotherapy (methods)
• Cisplatin (therapeutic use)
• Diffusion Magnetic Resonance Imaging
• Female
• Follow-Up Studies
• Gene Expression Profiling
• Genes, p16
• Humans
• Kaplan-Meier Estimate
• Male
• Middle Aged
• Neoplasm Recurrence, Local
• Oropharyngeal Neoplasms (chemistry, genetics, mortality, therapy)
• Oxygen (analysis)
• Prognosis
• Treatment Outcome